<DOC>
	<DOCNO>NCT02038049</DOCNO>
	<brief_summary>The aim study determine monoclonal antibody VAY736 reduce disease activity relapsing-remitting multiple sclerosis ( RRMS ) compare placebo . The study also provide first safety tolerability information VAY736 RRMS patient .</brief_summary>
	<brief_title>A Study Assess Effect Single Infusion VAY736 Disease Activity Patients With Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>18 Years 55 Years Male Female Diagnosis MS define 2010 revise McDonald criterion ( Polman , et . al2011 ) . A relapsingremitting course disease : least 1 documented relapse previous 12 month ( within 30 day prior randomization ) , positive Gdenhancing lesion brain MRI scan screening . An Expanded Disability Status Scale ( EDSS ) score 05.0 inclusive screening . No evidence relapse within 30 day prior randomization . â€¢ A manifestation another type MS RRMS . Findings screen baseline brain MRI inconsistent diagnosis MS. History chronic disease immune system MS , know immunodeficiency syndrome Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose 4 month follow completion study . Unable undergo MRI scan due interalia , claustrophobia , incompatible cardiac pacemaker , ferromagnetic intracranial aneurysm clip , certain cochlear implant , certain ferromagnetic foreign body ( e.g . tattoo contain metal ) electronic device , metallic implant incompatible MRI . Unable receive gadoliniumbased MRI contrast agent due history hypersensitivity gadoliniumbased contrast agent , renal insufficiency impairment . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Sclerosis , Relapsing-Remitting Multiple Sclerosis , Magnetic Resonance Imaging , VAY736 , monoclonal antibody , gadolinium [ Gd ] -enhancing lesion , B-Cell</keyword>
</DOC>